Cancer Stem Cell and Embryonic Development-Associated Molecules Contribute to Prognostic Significance in Ovarian Cancer

2012 ◽  
Vol 22 (1) ◽  
pp. 23-29 ◽  
Author(s):  
Gulperi Oktem ◽  
Muzaffer Sanci ◽  
Ayhan Bilir ◽  
Yusuf Yildirim ◽  
Sibel D. Kececi ◽  
...  
Keyword(s):  
Stem Cell ◽  
Cancer Stem Cell ◽  
Histological Grade ◽  
Prognostic Significance ◽  
Notch Pathway ◽  
Mucinous Carcinoma ◽  
Clinicopathological Characteristics ◽  
Serous Carcinoma ◽  
Ovarian Carcinomas ◽  
Clinical Prognosis

ObjectivesEmbryonic molecules and cancer stem cell signaling resemble each other, and they organize cancer modality. We hypothesized that similar immunohistochemical expressions between tumor spheroids and patients’ samples compared with clinical relevance would give an important clue in patients’ prognosis.MethodsImmunohistochemical expression of c-kit, Notch1, Jagged1, and Delta1 in 50 cases of primary ovarian tumors (10 endometrioid, 10 serous, 10 mucinous adenocarcinoma, 10 borderline serous, and 10 borderline mucinous tumors) and MDAH-2774 spheroids were investigated. Results were compared in both spheroids and tumor samples with morphologic parameters (histological grade) and clinical data (age, stage, tumor size, and metastasis).ResultsHigh c-kit and Notch1 immunoreactivity was shown in spheroids, but interestingly immunoreactivity of these molecules in tumor samples was different from patients’ clinicopathological characteristics. In serous carcinoma, metastasis correlated with Notch1 immunoexpression; in mucinous carcinoma, Jagged1 immunohistochemistry correlated with grade, stage, and metastasis of tumor; in borderline serous and mucinous tumors, Jagged1 correlated with high grade. Moreover, Jagged1 correlated with stage and Notch1 with size in borderline mucinous tumor. Endometrioid carcinoma statistics showed that there was a correlation between age and Notch1 expression.ConclusionNotch1, Jagged1, and Delta1 expressions might be useful markers for clinical prognosis of ovarian carcinomas; and Notch pathway, one of the most intensively studied putative therapeutic targets, may be a useful marker for cancer. Consequently, Jagged1 could be a marker for tumor grades and Notch1 as a marker for metastases.

scholarly journals Immunohistochemical Biomarkers as a Surrogate of Molecular Analysis in Ovarian Carcinomas: A Review of the Literature

Diagnostics ◽  
2021 ◽  
Vol 11 (2) ◽  
pp. 199 ◽  
Author(s):  
Giacomo Santandrea ◽  
Simonetta Piana ◽  
Riccardo Valli ◽  
Magda Zanelli ◽  
Elisa Gasparini ◽  
...  
Keyword(s):  
Ovarian Carcinoma ◽  
Molecular Analysis ◽  
Immunohistochemical Analysis ◽  
Cost Effective ◽  
Mucinous Carcinoma ◽  
Serous Carcinoma ◽  
Malignant Neoplasms ◽  
Low Grade ◽  
Ovarian Carcinomas ◽  
Novel Target

The term “ovarian carcinoma” encompasses at least five different malignant neoplasms: high-grade serous carcinoma, low-grade serous carcinoma, endometrioid carcinoma, mucinous carcinoma, and clear cell carcinoma. These five histotypes demonstrated distinctive histological, molecular, and clinical features. The rise of novel target therapies and of a tailored oncological approach has demanded an integrated multidisciplinary approach in the setting of ovarian carcinoma. The need to implement a molecular-based classification in the worldwide diagnostic and therapeutic setting of ovarian cancer demanded a search for easy-to-use and cost-effective molecular-surrogate biomarkers, relying particularly on immunohistochemical analysis. The present review focuses on the role of immunohistochemistry as a surrogate of molecular analysis in the everyday diagnostic approach to ovarian carcinomas.

scholarly journals Clinicopathological characteristics and prognostic value of the cancer stem cell marker ALDH1 in ovarian cancer: a meta-analysis

2018 ◽  
Vol Volume 11 ◽  
pp. 1821-1831 ◽  
Author(s):  
Wenge Zhao ◽  
Chuanxin Zang ◽  
Tingting Zhang ◽  
Jia Li ◽  
Ruijuan Liu ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Stem Cell ◽  
Cancer Stem Cell ◽  
Prognostic Value ◽  
Meta Analysis ◽  
Clinicopathological Characteristics ◽  
Stem Cell Marker ◽  
Cancer Stem Cell Marker ◽  
Cell Marker

scholarly journals Expression of the cancer stem cell marker SSEA1 is associated with poor survival in metastatic high-grade serous carcinoma

2020 ◽  
Vol 477 (5) ◽  
pp. 677-685
Author(s):  
Ben Davidson ◽  
Arild Holth ◽  
Hiep Phuc Dong
Keyword(s):  
Stem Cell ◽  
Survival Analysis ◽  
Cancer Stem Cell ◽  
Ovarian Carcinoma ◽  
Progression Free Survival ◽  
Stem Cell Marker ◽  
Serous Carcinoma ◽  
High Grade ◽  
Poor Survival ◽  
Free Survival

Abstract The objective of the present study was to perform a quantitative analysis of cancer stem cell (CSC) marker expression in ovarian carcinoma effusions. The clinical role of SSEA1 in metastatic high-grade serous carcinoma (HGSC) was additionally analyzed. CD133, Nanog, SOX2, Oct3/4, SSEA1, and SSEA4 protein expressions were quantitatively analyzed using flow cytometry (FCM) in 24 effusions. SSEA1 expression by immunohistochemistry was analyzed in 384 HGSC effusions. Highly variable expression of CSC markers by FCM was observed, ranging from 0 to 78% of Ber-EP4-positive cells in the case of CD133, with the largest number of negative specimens seen for SSEA4. SSEA1 expression by immunohistochemistry was found in HGSC cells in 336/384 (89%) effusions, most commonly focally (< 5% of cells). SSEA1 was overexpressed in post-chemotherapy disease recurrence specimens compared with chemo-naïve HGSC effusions tapped at diagnosis (p = 0.029). In univariate survival analysis, higher SSEA1 expression was significantly associated with poor overall survival (p = 0.047) and progression-free survival (p = 0.018), though it failed to retain its prognostic role in Cox multivariate survival analysis in which it was analyzed with clinical parameters (p = 0.059 and p = 0.111 for overall and progression-free survival, respectively). In conclusion, CSC markers are variably expressed in ovarian carcinoma effusions. SSEA1 expression is associated with disease progression and poor survival in metastatic HGSC. Silencing this molecule may have therapeutic relevance in this cancer.

scholarly journals Overexpression of SLC12A5 is associated with tumor progression and poor survival in ovarian carcinoma

2019 ◽  
Vol 29 (8) ◽  
pp. 1280-1284
Author(s):  
Gui-Ping Yang ◽  
Wei-Peng He ◽  
Jin-Feng Tan ◽  
Zun-Xian Yang ◽  
Rong-Rong Fan ◽  
...  
Keyword(s):  
Protein Expression ◽  
Ovarian Carcinoma ◽  
Patient Survival ◽  
Histological Grade ◽  
Prognostic Significance ◽  
Figo Stage ◽  
Protein Overexpression ◽  
Ovarian Carcinomas ◽  
The Status ◽  
Receiver Operator Curve Analysis

IntroductionThe solute carrier family 12 member 5 (SLC12A5) gene is playing a putative oncogenic role in colorectal carcinoma. However, the status of SLC12A5 amplification and expression in ovarian carcinoma and its potential clinical and/or prognostic significance has not yet been investigated.MethodsIn the present study, semi-quantitative staining and fluorescence in situ hybridization were used to investigate SLC12A5 protein expression and gene amplification levels. Samples were obtained from archival, formalin-fixed, paraffin-embedded pathological specimens consisting of 30 normal ovaries, 30 ovarian cystadenomas, 30 borderline ovarian tumors, and 147 invasive ovarian carcinomas. SLC12A5 immunohistochemical staining results, pathological parameters, and patient prognosis were then evaluated using various statistical models. Patient survival rate was also assessed using receiver-operator curve analysis.ResultsOur results revealed no SLC12A5 protein overexpression in normal ovaries. However, 7% of cystadenomas had SLC12A5 protein overexpression along with 17% of borderline tumors and 37% of ovarian carcinomas (P<0.01). Amplification of SLC12A5 was detected in 10.3% of ovarian carcinomas. Further correlational analyses showed that SLC12A5 protein overexpression in ovarian carcinomas was significantly associated with ascending histological grade, pT/pN/pM status, as well as FIGO stage (P<0.05). A subsequent univariate survival analysis of our ovarian carcinoma cohorts resulted in a significant association between SLC12A5 protein overexpression and decreased patient survival (44.3 and 85.9 months for high and low SLC12A5 protein expression, respectively; P<0.001). Importantly, additional multivariate analysis revealed that SLC12A5 protein expression was a significant, independent prognostic factor for overall survival in ovarian carcinoma patients (P=0.003).ConclusionsCollectively, these findings support the conclusion that SLC12A5 protein overexpression could indicate an invasive and/or aggressive phenotype of ovarian carcinoma. Future work will need to investigate whether SLC12A5 protein can serve as an independent prognostic molecular marker in patients with ovarian carcinoma.

scholarly journals Clinicopathologic and prognostic significance of LGR5, a cancer stem cell marker in patients with colorectal cancer

2019 ◽  
Vol 8 (4) ◽  
pp. CRC11 ◽  
Author(s):  
Chukwuemeka Ihemelandu ◽  
Aisha Naeem ◽  
Erika Parasido ◽  
Deborah Berry ◽  
Krysta Chaldekas ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Stem Cell ◽  
Cancer Stem Cell ◽  
Prognostic Marker ◽  
Prognostic Significance ◽  
Stem Cell Marker ◽  
Cancer Stem Cell Marker ◽  
Cell Marker ◽  
Independent Prognostic Marker ◽  
Lgr5 Expression

Aim: To analyze the clinicopathologic and prognostic significance of Leucine-rich repeat-containing G-protein-coupled receptor 5 (LGR5), a cancer stem cell marker expression in a cohort of colorectal cancer patients (CRC). Patients & methods: A total of 76 formalin-fixed paraffin-embedded tissue blocks of primary or metastatic tumors from 49 CRC patients were collected for duration 2009–2015. LGR5 expression was assessed through immunohistochemical staining of a tissue microarray. Results: LGR5 was significantly over expressed in CRC tissue samples and found to be a statistically significant independent prognostic marker for an improved overall survival. Conclusion: LGR5 expression was higher in colorectal cancer than in normal tissue. LGR5 was an independent prognostic marker for better clinical outcomes and might be used as a potential therapeutic target in CRCs.

scholarly journals The Secret Role of microRNAs in Cancer Stem Cell Development and Potential Therapy: A Notch-Pathway Approach

2015 ◽  
Vol 4 ◽  
Author(s):  
Marianna Prokopi ◽  
Christina A. Kousparou ◽  
Agamemnon A. Epenetos
Keyword(s):  
Stem Cell ◽  
Cancer Stem Cell ◽  
Notch Pathway ◽  
Cell Development

scholarly journals Cancer stem cell markers in breast cancer: pathological, clinical and prognostic significance

2011 ◽  
Vol 13 (6) ◽  
Author(s):  
H Raza Ali ◽  
Sarah-Jane Dawson ◽  
Fiona M Blows ◽  
Elena Provenzano ◽  
Paul D Pharoah ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Stem Cell ◽  
Cancer Stem Cell ◽  
Prognostic Significance ◽  
Stem Cell Markers ◽  
Cell Markers ◽  
Cancer Stem Cell Markers

scholarly journals The Cargo Protein MAP17 (PDZK1IP1) Regulates the Cancer Stem Cell Pool Activating the Notch Pathway by Abducting NUMB

2017 ◽  
Vol 23 (14) ◽  
pp. 3871-3883 ◽  
Author(s):  
Jose Manuel Garcia-Heredia ◽  
Antonio Lucena-Cacace ◽  
Eva M. Verdugo-Sivianes ◽  
Marco Pérez ◽  
Amancio Carnero
Keyword(s):  
Stem Cell ◽  
Cancer Stem Cell ◽  
Notch Pathway ◽  
Cell Pool ◽  
Cargo Protein ◽  
Stem Cell Pool

Cancer Stem Cell–Related Marker NANOG Expression in Ovarian Serous Tumors: A Clinicopathological Study of 159 Cases

2017 ◽  
Vol 27 (9) ◽  
pp. 2006-2013 ◽  
Author(s):  
Nataša Kenda Šuster ◽  
Snježana Frković Grazio ◽  
Irma Virant-Klun ◽  
Ivan Verdenik ◽  
Špela Smrkolj
Keyword(s):  
Stem Cell ◽  
Cancer Stem Cell ◽  
Signal Intensity ◽  
Serous Carcinoma ◽  
Low Grade ◽  
Clinical Parameters ◽  
High Grade ◽  
Ovarian Serous Carcinoma ◽  
Nanog Expression ◽  
Serous Tumors

ObjectiveThe objectives of this study were to assess cancer stem cell–related marker NANOG expression in ovarian serous tumors and to evaluate its prognostic significance in relation to ovarian serous carcinoma.MethodsNANOG protein expression was immunohistochemically evaluated in the ovarian tissue microarrays of 20 patients with benign ovarian serous tumors, 30 patients with borderline ovarian serous tumors, and 109 patients with ovarian serous carcinomas, from which 106 were of high-grade and 3 of low-grade morphology Immunohistochemical reaction was scored according to signal intensity and the percentage of positive cells in tumor samples. Pursuant to our summation of signal intensity and positive cell occurrence, we divided our samples into 4 groups: NANOG-negative, NANOG–slightly positive, NANOG–moderately positive, and NANOG–strongly positive group. Complete clinical data were obtained for the ovarian serous carcinoma group, and correlation between clinical data and NANOG expression was analyzed.ResultsA specific brown nuclear, or cytoplasmic reaction, was considered a positive NANOG staining. In terms of the ovarian serous carcinoma group, 69.7% were NANOG positive, 22.9% slightly positive, 22.9% moderately positive, and 23.9% strongly positive. All NANOG-positive cases were of high-grade morphology. Benign and borderline tumors and low-grade serous carcinomas were NANOG negative. There was no significant correlation between NANOG expression and clinical parameters in terms of the ovarian serous carcinoma group.ConclusionsPositive NANOG expression is significantly associated with high-grade ovarian serous carcinoma and is absent in benign, borderline, and low-grade serous lesions. In our study, there was no correlation between NANOG expression and clinical parameters, including its use in the prognosis of ovarian serous carcinoma.

Sign in / Sign up

Export Citation Format

Share Document